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Abstract 
Despite the use of multimodal treatments incorporating surgery, chemotherapy and radiotherapy, local 
control of gliomas remains a major challenge. The potential of a new treatment approach called indirect 
radio-chemo-beta therapy using the synergy created by combining methotrexate (MTX) with 
bromodeoxyuridine (BrUdR) under optimum energy x-ray irradiation is assessed. 9L rat gliosarcoma cells 
pre-treated with 0.01 μM MTX and/or 10 μM BrUdR were irradiated in vitro with 50 kVp, 125 kVp, 250 kVp, 
6 MV and 10 MV x-rays. The cytotoxicity was assessed using clonogenic survival as the radiobiological 
endpoint. The photon energy with maximum effect was determined using radiation sensitization 
enhancement factors at 10% clonogenic survival (SER10%). The cell cycle distribution was investigated 
using flow cytometric analysis with propidium iodide staining. Incorporation of BrUdR in the DNA was 
detected by the fluorescence of labelled anti-BrUdR antibodies. The radiation sensitization enhancement 
exhibits energy dependence with a maximum of 2.3 at 125 kVp for the combined drug treated cells. At 
this energy, the shape of the clonogenic survival curve of the pharmacological agents treated cells 
changes substantially. This change is interpreted as an increased lethality of the local radiation 
environment and is attributed to supplemented inhibition of DNA repair. Radiation induced chemo-beta 
therapy was demonstrated in vitro by the targeted activation of combined pharmacological agents with 
optimized energy tuning of x-ray beams on 9 L cells. Our results show that this is a highly effective form 
of chemo-radiation therapy. 
Keywords 
rays, x, efficiency, biological, increase, approach, energy, targeted, indirect, therapy, beta, chemo, radio 
Disciplines 
Engineering | Science and Technology Studies 
Publication Details 
Oktaria, S., Corde, S., Lerch, M. L. F., Konstantinov, K., Rosenfeld, A. B. & Tehei, M. (2015). Indirect radio-
chemo-beta therapy: a targeted approach to increase biological efficiency of x-rays based on energy. 
Physics in Medicine and Biology, 60 (20), 7847-7859. 
Authors 
Sianne Oktaria, Stephanie Corde, Michael L. F Lerch, Konstantin K. Konstantinov, Anatoly B. Rosenfeld, 
and Moeava Tehei 
This journal article is available at Research Online: https://ro.uow.edu.au/eispapers/4458 
Page 1 of 16 
Indirect radio-chemo-beta therapy:  a targeted approach to 
increase biological efficiency of X-rays based on energy 
 
Running heads: Indirect Radio-Chemo-Beta therapy 
 
Sianne Oktaria1,2,3, Stéphanie Corde1,4*, Michael L F Lerch1, Konstantin 
Konstantinov5, Anatoly B Rosenfeld1, and Moeava Tehei1,2,3 
1 Centre for Medical Radiation Physics, University of Wollongong, NSW, Australia 
2 Centre for Medical and Molecular Bioscience, University of Wollongong, NSW, Australia 
3 Illawarra Health and Medical Research Institute, University of Wollongong, NSW, Australia 
4Radiation Oncology Department, Prince of Wales Hospital, Randwick, NSW, Australia 




*Corresponding author. Address: Radiation Oncology Department, Prince of Wales hospital, High St, 
Randwick, NSW 2031, AUSTRALIA. Phone: +61-2-9382-2604. Fax: +61-2-9382-2550.  
 
Abstract  
Despite the use of multimodal treatments incorporating surgery, chemotherapy and radiotherapy, 
local control of gliomas remains a major challenge. The potential of a new treatment approach called 
indirect radio-chemo-beta therapy using the synergy created by combining methotrexate (MTX) with 
bromodeoxyuridine (BrUdR) under optimum energy X-ray irradiation is assessed. 9L rat 
gliosarcoma cells pre-treated with 0.01 µM MTX and/or 10 µM BrUdR were irradiated in vitro with 
50 kVp, 125 kVp, 250 kVp, 6 MV and 10 MV X-rays. The cytotoxicity was assessed using 
clonogenic survival as the radiobiological endpoint. The photon energy with maximum effect was 
determined using radiation sensitization enhancement factors at 10% clonogenic survival (SER10%). 
The cell cycle distribution was investigated using flow cytometric analysis with propidium iodide 
staining. Incorporation of BrUdR in the DNA was detected by the fluorescence of labeled anti-
BrUdR antibodies. The radiation sensitization enhancement exhibits energy dependence with a 
maximum of 2.3 at 125 kVp for the combined drug treated cells. At this energy, the shape of the 
clonogenic survival curve of the pharmacological agents treated cells changes substantially. This 
change is interpreted as an increased lethality of the local radiation environment and is attributed to 
supplemented inhibition of DNA repair. Radiation induced chemo-beta therapy was demonstrated in 
vitro by the targeted activation of combined pharmacological agents with optimized energy tuning of 
X-ray beams on 9L cells. Our results show that this is a highly effective form of chemo-radiation 
therapy.  
 






 Gliomas are among the most frequent primary brain tumours in adults, with an incidence of 
approximately 5–11/100,000 among the population per year in industrial countries. The advent of 
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imaging techniques has made early diagnosis possible and recently there has been some 
improvement in treatment techniques leading to increases in the median 5-year survival of patients 
(Malmstrom et al. 2012; Scott et al. 2011; Stupp et al. 2009). However, the treatment of high-grade 
gliomas remains a major challenge and is currently palliative rather than curative. Despite different 
multimodal treatments, including surgery, chemotherapy and radiotherapy, these gliomas remain 
extremely radioresistant while the surrounding normal tissues are comparably radiosensitive, 
especially in children.  
 Although dose enhancement improves local control of tumours, it is limited by the 
tolerance of healthy tissue.  One of the main reasons for radiotherapy failure is post-treatment 
tumour regrowth. Consequently improved therapeutic ratios are needed. These rely on the 
development of new mechanisms to increase the X-ray dosage in tumours while sparing the 
surrounding tissues. Similarly, adjuvant chemotherapy generally fails to improve patient outcomes 
because of inadequate drug delivery inside the tumour (Behin et al. 2003; Bredel 2001). 
Considerable efforts have been made to optimize chemo-radiotherapy treatments of tumours by 
increasing both the chemotherapeutic drug concentration and the radiation dose while minimising 
the effect on healthy tissues (Behin et al. 2003). Linking drug activation to an optimized energy 
tuning of X-ray beams could permit a highly effective chemo-radiation therapy that significantly 
limits drug and radiation toxicity for healthy tissues. 
 Many anticancer drugs act on nucleotide biosynthesis to destroy rapidly cycling tumour 
cells. For example, they may inhibit enzymes involved in tetrahydrofolate synthesis such as 
dihydrofolate reductase (DHFR), or in thymidine synthesis such as thymidylate synthetase (TS). 
The well-known antimetabolite chemotherapeutic agents methotrexate (MTX), 5-Fluorouracil 
(5FU) and raltitrexed break the thymidylate synthesis cycle by respectively blocking DHFR 
(Huennekens 1994; Tehei et al. 2006) or TS enzymes (Pinedo et al. 1988). The folate analogue 
MTX is taken up in the cell by folate receptor-mediated endocytosis and it has a high affinity for 
those receptors. The cell surface receptor for folate is overexpressed in a large number of tumours 
including brain cancer. As the expression of folate receptors is low in normal cells, MTX has a high 
selectivity for brain tumours and does not normally accumulate in healthy tissue (Lu et al. 2003; 
Wang et al. 1998; Weitman et al. 1992). 
 Halogenated pyrimidine analogues, such as bromodeoxyuridine (BrUdR) or 
iododeoxyuridine (IUdR), are radiosensitising drugs which compete with thymidine for 
incorporation into the structure of DNA. Consequently, a halogenated compound (containing 
bromine Z=35 or iodine Z=53) can be introduced directly into DNA - this is the reason why such 
compounds are strong candidates for both radioactive Auger emitter (Kassis et al. 1982; Kassis et 
al. 1998) and synchrotron radiation-induced Auger cascade studies (Corde et al. 2004; Laster et al. 
1993; Usami et al. 1991). These latter in vitro studies have demonstrated a significant increase in 
the Auger enhancement ratio, up to a factor of three, for synchrotron X-ray irradiation above the 
iodine K-absorption edge (Laster et al. 1993) and for a 100kVp x-ray beam (Karnas et al. 1999). 
Useful radiosensitization with thymidine analogues depends on achieving significant uptake into the 
cancer cell DNA and minimising the number of cells that have no thymidine replacement. MTX and 
5FU inhibition of the TS cycle has been shown to increase the incorporation of bromine or iodine 
thymidine analogues into cells (Benson et al. 1985; Bruce-Gregorios et al. 1991; Kassis et al. 
2000).  
Page 3 of 16 
 Earlier synchrotron radiation study in the keV energy range using halogenated component 
revealed that the dose enhancement is dependent on the beam energy, with an optimum therapeutic 
irradiation based on the mass energy-absorption coefficient of the target due to the presence of 
halogenated component (Corde et al. 2004). Conventional kilovoltage and megavoltage X-ray 
beams are widely used for cancer radiotherapy treatment and provide a broader irradiation energy 
range. In the megavoltage range of energies (< 20 MeV), photon beams mainly interact with matter 
by Compton scattering and pair production processes. These processes can produce high-energy 
electrons with a long-range energy deposition. In the kilovoltage range, the demonstrated dose 
enhancement is mainly due to the photoelectric effect. The resulting Auger electrons have a shorter 
range and can deposit energy with greater radiobiological effectiveness due to a high linear energy 
transfer in aqueous solution (Corde et al. 2004).  
In this work, we investigate a new modality for radioresistant brain tumour treatment called 
indirect radio-chemo-beta therapy using the synergy of the chemotherapy drug methotrexate, the 
halogenated pyrimidine bromodeoxyuridine containing a high Z (atomic number) atom and X-ray 
radiation beams. We study the optimum energy of our treatment by probing the radiation 
sensitization enhancement factor along the energy spectrum from 50 kVp to 10 MV. Using 
clonogenic survival as our radiobiological endpoint, the radiation sensitization enhancement is 
shown to be energy dependent, with a maximum at 125 kVp for cells pre-treated with the combined 
drugs. The experimental optimal energy value of the enhancement ratio produced in the presence of 
the BrUdR agrees with theoretical predictions (Corde et al. 2004). The methotrexate enhances 
radiation sensitization by inhibiting production of the endogenous substrate dTMP and therefore 
decreasing DNA repair. The associated cell survival curves demonstrate a significant change in 
shape, indicative of increased lethality of the local radiation environment possibly instigated by the 
inhibition of the DNA repair. Contributing mechanisms for the observed increased lethality have 
been investigated using flow cytometry and are discussed. Bromide incorporation was quantified 
using immunocytochemical staining of BrUdR. Our data obtained in this study emphasizes the 
importance of linking drug activation to a precise targeting of optimal energy X-ray beams. This 
permits a highly effective chemo-radiation therapy that significantly limits drug and radiation 
toxicity for healthy tissues. 
 
2. Materials and Methods  
 
2.1. Cell culture 
 
9L rat gliosarcoma cell line derived from N-nitrosomethylurea-induced tumor was obtained from 
the European Collection of Cell Cultures (ECACC). Cells were maintained in exponential growth in 
DMEM (Invitrogen, AU) with L-Glutamine and supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin (Pen Strep) at 37°C in a humidified incubator with 5% CO2 in air.  
 
2.2. Drugs treatment and cytotoxicity  
 
Methotrexate (MTX) and 5-bromo-2’-deoxyuridine (BrUdR) (Sigma-Aldrich, MO, USA) were 
prepared in Hanks’ balanced salt solution and stored at –20°C. 9L cells seeded in T12.5 cm2 flasks 
in complete DMEM were allowed to attach and divide for 48 hours. Then, medium was replaced 
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and cells were incubated with 0.01 µM MTX and/or 10 µM BrUdR. After a two doubling times 
incubation with the drugs, the cytotoxic effect of drugs was determined by clonogenic assay.  
 
2.3. Irradiation procedures 
 
Confluent cell cultures were irradiated in T12.5 cm2 flasks following a two doubling times 
incubation period with drugs. Prior to irradiation, the flasks were completely filled with drugs-
containing medium (drugs concentration maintained). The Nucletron Oldelft Therapax DXT 300 
Series 3 Orthovoltage unit (Nucletron B.V., Veenendaal, The Netherlands) was used for cellular 
irradiation in the kilovoltage energy range. The beam qualities correspond to 50 kVp with 
additional filtration of 1.65 mm Al (HVL=1.58 mm Al), 125 kVp with additional filtration of 0.1 
mm Cu and 2.5 mm Al (HVL=6.64 mm Al) and 250 kVp with additional filtration of 0.3 mm Sn, 
0.5 mm Cu and 1.5 mm Al (HVL=2.4 mm Cu). Flasks were placed vertically 50 cm from the source 
with cell monolayers facing a 6x8 cm2 applicator. The Axesse Elekta linear accelerator (LINAC) 
with beam modulator (Elekta AB, Kungstensgatan, Stockholm, Sweded) was used for cellular 
irradiation in the megavoltage energy range. Flasks were placed vertically at a depth of 2.2 cm and 
1.5 cm in solid water to match the Dmax depth of the 10 MV and 6 MV photon field, respectively. 
Solid water was placed both behind and around the sides of the flasks, primarily to provide 
adequate photon backscattering. All doses (1, 2, 3, 5 and 8 Gy) were delivered in a single fraction at 
room temperature. Unirradiated control samples (with and without drugs) were handled under the 
same conditions as the irradiated samples.  
 
2.4. Clonogenic survival  
 
Cell survival was measured by the colony-forming assay (Puck et al. 1956). Cells were plated after 
irradiation at low densities to achieve approximately 100 colonies after fifteen doubling times in 
100-mm tissue culture dishes containing 10 mL of complete cell medium. Colonies were fixed and 
stained with a mixture solution of 25% crystal violet and 75% ethanol. Only colonies containing 
more than 50 cells were counted as surviving. 
 
The surviving fraction (SF) expressed as a function of dose (D) curves were fitted using IgorPro 
software using the linear quadratic (LQ) model where α [Gy-1] and β 
[Gy-2] are the radiosentivity parameters (Chadwick et al. 1973; Curtis 1986; Fertil et al. 1981; 
1985). 
 
2.5. Sensitization enhancement Ratio 
 
To quantify the increase in efficiency of treatment modality compared to non-treated control, we 
used SER10% or the ratio of the doses necessary to obtain the same radiobiological effect, i.e 10% 
cell survival.   
 
2.6. Cell cycle analysis 
 
Measurements of the cell cycle distribution were performed using flow cytometric analysis with 
propidium iodide (PI) staining. The method used was derived from Vine et al. (2007). Cells (2.0 x 
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106) were treated with a solution containing 40 µg/mL PI, 100 µg/mL RNase A, and PBS (pH 7.4) 




Cells incorporating BrUdR after drug treatment were detected using fluorescently labelled anti-
BrUdR antibodies. The anti-BrdU mouse monoclonal antibody (Clone MoBU-1) conjugated to 
Alexa Fluor 488 (highly specific to BrUdR incorporated into the DNA) from Molecular Probe 
(Invitrogen, AU) was used. The assay was carried out using an acid denaturation method as per 
manufacturer’s references with minor modifications.  
 
2.8. Fluorescence measurements 
 
The stained nuclei were analysed for both DNA-PI and Alexa Fluor-PI fluorescence using a Becton 
Dickinson fluorescence-activated cell sorting (FACS) flow cytometer (BD LSR II; BD Biosciences, 
USA) with excitation at 488 nm. The resulting DNA distribution was analysed using FlowJo 
software (V9.6.2; Tree Star Inc., USA). 
 
2.8. Statistical Analysis 
 
Statistical analysis of toxicity data was performed using a two-tailed Student's t-test using the 
assumption of equal variance (p-value ≤0.05 considered significant).  
 
3. Results  
 
3.1. Energy dependence of the radiation sensitization enhancement  
 
The survival curves show that at all energies, combining drugs (0.01 µM MTX and 10 µM BrUdR) 
with radiation is more effective than radiation alone (Figure 1a-1e). The enhancement exhibits an 
energy dependency and the maximum effect is observed at 125 kVp with a SER10% of 2.3 (Figures 1 
and 2, Table 1).  Figure 3 shows the dose gain produced by the replacement of water by bromine, as 
calculated by the ratio of the total mass energy absorption of bromine to water relative to the 
incident photon energy: (𝜇𝑒𝑒 𝜌)⁄ 𝑏𝑏𝑏𝑏𝑏𝑒𝑒 (𝜇𝑒𝑒 𝜌)⁄ 𝑤𝑤𝑤𝑒𝑏⁄ . The maximum value is at 40 keV, which 
is comparable to the effective energy of the spectrum emitted from the orthovoltage X-ray unit at 
125 kVp. 
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Figure 1. Cell survival curves of 9L cells after irradiation at energies of 50 kVp (a), 125 kVp (b), 250 kVp (c), 6 MV (d), and 10 MV (e) 
with or without drugs (0.01 µM MTX, 10 µM BrUdR and the combination (0.01 µM MTX and 10 µM BrUdR)). Surviving fractions of 
irradiated cells only (no drugs) and with drugs were normalized to non-irradiated control and non-irradiated drugs-treated cells sample, 
respectively. Each data point represents the means ± SD of at least two independent experiments (each triplicate). 
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Figure 2. Sensitization enhancement ratio at 10% surviving fraction (SER10%) of combined drugs 




Figure 3. Ratio of the mass energy absorption coefficient of bromine to water vs. photon energy 
(keV). 
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3.2. Efficacy of the different treatments at the optimum energy 125 kVp 
 
Figure 1b shows clonogenic cell survival results for different pharmacological treatments, the 
corresponding radiobiological parameters (α, β) are presented in table 1. In the presence of MTX 
the 9L cells have a similar radiosensitivity as the untreated cells (Figure 1b). This radiosensitivity 
increases in the presence of BrUdR with an additional effect when BrUdR is combined with MTX, 
confirming the radiation enhancement ability of the drug combination; a statistically significant 
difference between the groups was found (P<0.003).  The 9L cells treated with the drug 
combination exhibit a linear trend in the survival curve (Figure 1b, Table 1). We believe that a 
synergistic effect appears as an increase in the SER10% as a result of the interaction with the BrUdR 
combined with the additional decrease of the DNA repair generated by MTX. The overall combined 
effect is supra-additive, i.e. greater than the sum of the individual components summed together. 
 
Table 1. Values of the linear-quadratic model parameters α and β and SER10% from 9L cells treated 
with ionising radiation only and BrUdR/MTX-sensitized radiation dose survival curves of different 
energies. 
Energies Treatment α (Gy-1)a β  (Gy-2)a SER10%b 
50kVp XIRc 
DRUGSd  
0.151 ± 0.019 
0.284 ± 0.009 
0.018 ± 0.006  







0.213 ± 0.008 
0.192 ± 0.013  
0.295 ± 0.035 
0.521 ± 0.028  
0.002 ± 0.001  
0.004 ± 0.002 









0.319 ± 0.025  
0.038 ± 0.000  





0.200 ± 0.015 
0.335 ± 0.024 
0.010 ± 0.002 





0.200 ± 0.062 
0.218 ± 0.069 
0.013 ± 0.008 
0.021 ± 0.010 
1.0 
1.2 
aα and β are linear-quadratic model parameters. Values are presented as mean ± SD. 
bSER10% = sensitization enhancement ratio at 10% surviving fraction.  
cXIR = X-ray radiation only.  
dDRUGS = MTX (0.01 µM) and BrUdR (10 µM) combination. 
e N/A = not applicable. 
 
3.3. Drug cytoxicity  
 
Figure 4 shows that the 0.01 µM MTX and/or 10 µM BrUdR drug treatment of 9L cells induces 
toxic effects on the clonogenic survival. Surviving fractions for the MTX and the BrUdR treatments 
alone are similar with values of 0.61 ± 0.05 (MTX vs untreated) and 0.60 ± 0.09 (BrUdR vs 
untreated), respectively. The toxicity of the combined treatment is increased with a surviving 
fraction value of 0.43 ± 0.07. 
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Figure 4. Cytotoxicity of the pharmacological treatments: 0.01 µM MTX, 10 µM BrUdR and the 
combination (0.01 µM MTX and 10 µM BrUdR) without radiation. Clonogenic surviving fractions 
were normalized to the untreated control. Bars are ± one standard deviation (±SD). p<0.05. 
 
 
3.4. Cell cycle analysis and bromine incorporation into DNA 
 
Figure 5 shows a representative DNA histogram of PI stained 9L cells. The histogram profile of 
untreated control cells is shown in Figure 5a. Following drug incubation there is a decrease of cells 
in the G2/M phase associated with an accumulation into the S-phase (Figure 5b). For the drugs 
combined with radiation, an accumulation of the DNA in the pre-apoptotic sub-G1 peak is 
observed. The results show that the other cell cycle phases completely disappear (Figure 5c). 
The incorporation of BrUdR in DNA was quantified using immunocytochemical staining. The cells 
were also counterstained with PI for DNA quantification. Alexa Fluor 488 fluorescent cells are 
considered BrUdR-positive cells. The BrUdR labelling index (LI) is the ratio of the number of 
BrUdR-positive cells to the total number of cells. The LIs of the cells treated with BrUdR and the 
combination MTX/BrUdR are similar, with values of 38.4%±3.4% and 38.4%±3.1% respectively. 
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Figure 5. Single parametric DNA diagrams of 9L cells stained with PI. Measurements were 
performed on a FACS LSR II flow cytometer without drugs and irradiation (a), with drugs 
alone (0.01 µM MTX and 10 µM BrUdR) (b), drugs (0.01 µM MTX and 10 µM BrUdR) 
combined with 5 Gy X-rays radiation of 125 kVp (c). FACS plots are representative of at 
least three independent experiments.  
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4. Discussion  
 The experimental optimum energy for the maximum enhancement of BrUdR+MTX is at 
125 kVp. This provides the highest SER10% of 2.3 (Figures 1 and 2, Table 1). The 125 kVp beam 
produces an effective energy of 46 keV which lies close to the energy predicted to maximize the 
dose enhancement (i.e. 40 keV) using BrUdR (Figure 3). Our results confirm the theoretical 
expectation (Figure 3) according to the maximum energy deposited in bromine compared to water 
and are thus in agreement with the formalism described by the authors (Corde et al. 2004). Our 
results also suggest that the production of photoelectrons and the resulting high LET Auger 
electrons have an important role in the enhancement energy dependence. Two earlier studies 
investigated the dose enhancement induced by halogenated pyrimidines on cells (Corde et al. 2004; 
Franken et al. 1997). Using human head and neck squamous carcinoma SQ20B and 50 keV 
monochromatic synchrotron beam (Corde et al. 2004) probed the dose enhancement induced by 10 
µM IUdR and found SER10% = 2.62. The significance of our work is that we were able to obtain 
similar SER10% results using a widely accessible X-ray treatment modality (orthovoltage machine as 
opposed to a synchrotron facility) with a considerably lower beam flux (compared to that at a 
synchrotron) and a much broader X-ray photon spectrum (i.e. not ideally optimized compared to the 
monoenergetic X-ray beam available at a synchrotron). Furthermore, we obtained comparable 
SER10% values using drugs with a lower atomic number (bromine compared to iodine) and we 
should therefore expect a higher SER10% using our treatment with IUdR.  
 If megavoltage beams would be in principle clinically more appropriate to treat deep-seated 
tumours, the MV treatments (Table 1) are not as effective as the treatment at 125 kVp, which was 
expected by the theoretical calculation (Figure 3). Based on the latter, we should however observe 
much lower SER10% values in this MV range. Other studies using cisplatin (Rousseau et al. 2010) 
and carboplatin (Bobyk et al. 2012) demonstrated an equivalent therapeutic response when the drug 
is combined with either 6 MV photons or synchrotron X-rays at the K-edge of platinum (78.8 keV). 
Our calculation for the element platinum suggests however that the optimum X-ray energy for the 
dose enhancement is also at about 40 keV and not at 78.8 keV. In a realistic clinical treatment 
scenario, kilovoltage beams could lead to appropriate dose distribution depending on patient size 
and localization of tumours. However beam energy optimization should not only take into account 
high-Z element but also overall irradiation geometry. Therefore the practical optimal beam energy 
might be ultimately higher than predicted in simple geometry. 
 To enrich our understanding of the radiobiological mechanism that may occur during our 
treatments, we study their effects at the dose enhancement optimal X-ray energy i.e 125 kVp, only 
more deeply. Several degrees of thymidine replacement by BrUdR have been observed on different 
cell lines (Delihas et al. 1962; Nagashima et al. 1985). Our result (38%) is reasonably close to the 
value (49%) reported on 9L at a similar BrUdR concentration (Nagashima and Hoshino 1985). 
Although MTX is toxic for 9L cells (Figure 4), it does not increase their radiosensitivity (Figure 1b) 
as they are not exponentially growing, being confluent in plateau phase (Spittle 1978). This 
observation is also a consequence of the MTX concentration used, which was 200-fold below the 
half maximal inhibitory concentration (IC50).  
 Individually MTX and BrUdR provoked similar toxicities on the 9L cells (Figure 4).  
However, while irradiation of BrUdR treated cells showed a significant decrease in cell survival 
there was no such decrease using MTX (Figure 1b). The significant decrease observed with BrUdR 
is related to its high-Z properties, as suggested above, and therefore its ability to act as a radiation 
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enhancer. Our results are consistent with previously published data (Larson et al. 1989). It has been 
suggested that the underlying mechanisms behind the increased radiation sensitivity induced by 
halogenated pyrimidines is due to an increase in the direct lethal DNA damages and/or a decrease of 
repair of sublethal damages (Franken et al. 2013; Franken et al. 1997). Both the α and β parameters 
increased for the BrUdR treatment. The latter may indicate that there are increases of direct lethal 
DNA damages and accumulation of sublethal damages as suggested in (Franken et al. 2013; 
Franken et al. 1997). Addition of MTX exacerbates DNA damage repair impairment with 
linearization of the survival curve. 
 Data from the LQ model indicates an increased linearity of the survival curve in the 
presence of the drug combination (Figure 1b). The LQ model parameters indicate an increased 
radiosensitivity when the drug combination is present (Table 1). The increased linearization is 
indicative of a change in the local radiation spectrum. This observation suggests that more direct 
damage effects have occurred. This damage could be due to an enhancement of the lethal low 
energy electron field (resulting from the internalization of the high-Z drug component), which may 
be further magnified by a decrease in DNA repair (instigated by the presence of the thymidine 
analogue). The corresponding survival curve, obtained under the same irradiation conditions, for 
BrUdR is not linear with a lower α value (Figure 1b, Table 1). We conclude that the increased 
linearity, with a higher α value, is due to a synergetic combination of direct lethal DNA damage 
with a marked decrease in the DNA repair modulated by the MTX initiating apoptosis as suggested 
by the flow cytometric analysis (Figure 5C). 
 Pre-clinical evaluation of our radiation induced chemo-beta therapy in animal models is an 
important step toward potential clinical application. The complexity of physiological factors in vivo 
can largely affect the drugs delivery in tumours and lead to different tumour response to the 
treatment. To validate the effects observed in vitro on 9L gliosarcoma cell line, the model can be 
translated directly in vivo by using the Fischer 344 rat brain tumour model (Weizsaecker et al. 
1981). Recently the blood-brain barrier disruption (Angelov et al. 2009) and nasal chemotherapy 
(Shingaki et al. 2010) have been explored as an alternative for administering anticancer drugs such 
as MTX for the treatment of brain tumours. Shingaki et al. (2010) investigated intranasal delivery 
of MTX to brain tumours (9L) and demonstrated significant direct transport of MTX to the brain. A 
reasonable approach for future in vivo experiments would be to use those techniques to deliver 




We have demonstrated the efficacy of radiation induced chemo-beta therapy. Our innovative 
multimodal approach for radio resistant brain tumour treatment uses the synergy of pharmacological 
treatments, an antimetabolite chemotherapy drug, MTX, and the halogenated pyrimidine, BrUdR, 
together with widely accessible hospital X-ray radiations. This study emphasizes the importance of 
linking drug activation to precise targeting of optimized energy X-ray beams leading to a highly 
effective chemo-radiation therapy. This is achievable with a significant decrease in the required 
drug and radiation dosage otherwise required for the same treatment outcome, which, if able to be 
translated into clinical practice, could potentially limit the toxicity of such a treatment to 
surrounding healthy tissues. 
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